Results 81 to 90 of about 67,365 (299)

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

Journal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella, Marcello Cottini, Rory Chan   +2 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis

JAMA Ophthalmology
ImportanceEmerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.ObjectiveTo evaluate whether being prescribed a ...
Mohan, Nitesh, Srivastava, Sunil K., Schulgit, Matthew J., Nowacki, Amy S., Kaelber, David C., Sharma, Sumit   +5 more
openaire   +2 more sources

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain

Neural Regeneration Research
The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, José Antonio Lamas, Lucas C González-Matías, Federico Mallo   +5 more
doaj   +1 more source

Body‐integrated photonic biosensors: Illuminating the path to active healthcare

FlexMat, EarlyView.
Body‐integrated photonic biosensors are promising tools for active healthcare. These optical devices can be worn, implanted, or swallowed to monitor health signals continuously. This review introduces key sensing modalities, including fluorescence, colorimetry, SPR, LSPR, SERS, and light‐modulating materials.
Jiayue Gu, Xingming Wen, Qihang Yan, Yining Zhao, Linghao Yuan, Siyuan Chen, Yue Ma, Zhengyue Fang, Dong Lei, Yuxin Liu, Ze Xiong   +10 more
wiley   +1 more source

Decision letter for "No effects of a six‐week intervention with glucagon‐like peptide‐1 receptor analogue on pancreatic volume and edema in obese men without diabetes"

, 2020

openalex   +1 more source

Decision letter for "Cardiovascular risk profiles: A cross‐sectional study evaluating the generalisability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials Rewind , Leader and Sustain ‐6 to the real‐world type 2 diabetes population in the UK"

, 2021

openalex   +1 more source